[China BD 2023] Insilico Medicine and Exelixis enters a 800 million USD license on USP1 Inhibitor ISM3091

Announced Date: 2023-09-12 (September 12, 2023)

Asset Name: ISM3091

Licensor: InSilico Medicine (China)

Licensee (Buyer): Exelixis, Inc（US）

.

Asset Modality: Small  Molecule

Asset Target: USP1 Inhibitor

Potential Indication: BRCA-mutant tumors

Current Stage: IND clearance

.

Scope of Authority:

 Insilico granted Exelixis an exclusive, worldwide license to develop and commercialize ISM3091, and other USP1-targeting compounds. 

.

Deal Detail:

Upfront payment of  $80 million,

Development, commercial, and sales-based milestone payments, may up to $800 million .

Tiered royalties on net sales.

.

Link:

Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor | Exelixis, Inc.

.

Note:

Chinese Name of Insilico Medicine  英矽智能